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Abstract Sulfasalazine has long been used for the treatment
of rheumatoid arthritis and is often chosen as a first-line
treatment. Here, we report a case of sulfasalazine-induced
autoimmune thrombocytopenia and review the mechanisms
behind drug-induced immune thrombocytopenia (DITP) and
the approach to its diagnosis and management.
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Sulfasalazine (SSZ) has been used for the treatment of rheu-
matoid arthritis (RA) for decades. Given its safety profile (es-
pecially lack of teratogenicity), ease of administration and cost, it
is often used as first line treatment. Myelosuppression is a recog-
nized side effect of sulfasalazine, as is the development of drug
induced-Systemic Lupus Erythematosus (SLE) or SLE-like dis-
ease [1], which may also result in blood dyscrasias. Here, we
report a case of sulfasalazine induced autoimmune thrombocyto-
penia, which rapidly settled on stopping the drug, highlighting
the importance of considering this rare complication of
sulfasalazine therapy. We also review the mechanisms behind
drug induced immune thrombocytopenia (DITP) and the ap-
proach to its diagnosis and management.
Our patient, a 67 year old Caucasian man, presented with
symmetrical synovitis of knees, shoulders, and small joints of
the hands. A diagnosis of seronegative RA was made. ANA
was negative at time of diagnosis. He was commenced on
sulfasalazine, with remission of arthritis 4 months later. His
other medication consisted of diclofenac 50 mg, which he
took up to twice a day, as needed. Two years after diagnosis,
at a routine follow up, it was noted that his platelet count had
been steadily declining for 3 months, from an average count of
230 × 109/L to 90 × 109/L. The patient himself was well,
without rash, symptoms of bleeding, or history of recent ill-
ness and his RA remained in remission. Medication was un-
changed. Examination was unremarkable; the patient was afe-
brile, with no evidence of purpura, or bleeding, and no lymph-
adenopathy or hepatosplenomegaly.
Repeat platelet count was 87 × 109/L. Rest of the full blood
count, peripheral blood film, and INR (international normalized
ratio) were unremarkable. Sulfasalazine was stopped, and the
patient continued to take diclofenac as needed.
Immunology testing demonstrated negative ANA, but di-
rect anti-platelet IgM and IgG were positive, consistent with
autoimmune thrombocytopenia.
Two weeks after SSZ was stopped, the platelet count had
increased to 150 × 109/L. Three months later, platelet count
was steady at 200 × 109/L, and Anti-platelet IgM was nega-
tive. The patient’s arthritis remained in remission, and no fur-
ther DMARDs were initiated.
Only one case report exists that describes an associa-
tion of sulfasalazine with an autoimmune thrombocytope-
nia, although that case was also associated with positivity
to lupus anticoagulant. [2] Although NSAIDs are a report-
ed cause of thrombocytopenia, in our case, this is ex-
tremely unlikely to be the causative drug, since diclofenac
was continued while sulfasalazine was ceased, and plate-
let count still normalized.
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Thrombocytopenia is defined as a platelet count of below
150 × 109/L. Prediction of bleeding risk by platelet count is
unreliable [3], but generally, platelet counts above 50 × 109/L
usually do not lead to bleeding, unless platelet dysfunction is
also present. At platelet counts of less than 30 × 109/L, spon-
taneous bleeding and purpura may occur, with clinically sig-
nificant bleeding occurring when count is under 10 × 109/L
[4]. Thrombosis may also be associated with a low platelet
count, particularly in heparin-induced thrombocytopenia.
Drug induced immune thrombocytopenia (DITP) is a rare
cause of immune thrombocytopenia, with an estimated inci-
dence of ten cases per million per year [5], and is most com-
mon in critically unwell, hospitalized patients. DITP has been
reported to occur via at least six different mechanisms [6, 7]
(see Table 1).
Testing for specific antibodies for DITP, such drug de-
pendent antibodies can be complex and time consuming,
and is available only in a few laboratories. Therefore, a
set of clinical criteria have been proposed as a more prac-
tical way of establishing the presence of drug induced ITP
based on systematic review of existing literature [8] (see
Table 2).
The management of a patient with suspected thrombocyto-
penia is aimed at establishing the cause, and assessing and
treating those with, or at risk of, clinically significant bleeding.
History taking includes questioning for evidence of bleeding,
constitutional symptoms such as fevers, sweats, weight loss,
which may indicate an underlying neoplastic or infective
cause for low platelets, and a drug history to look for
pre-disposing medications. Examination should look for
purpura and other signs of bleeding, as well as
hepatosplenomegaly and lymphadenopathy to look for
evidence of myelodysplasia.
Initial investigations should include a full blood
count, to rule out leukopenia and anaemia. A peripheral
blood film is essential, to assess for falsely low platelet
count secondary to platelet clumping. Clotting tests
such as INR are useful, to assess bleeding risk further,
and viral screen for HIV and Hepatitis C should be
considered [4].
Management of DITP is to stop the precipitating drug. For
those with a platelet count of above 10 × 109/L without bleed-
ing, or other risk factors for bleeding, monitoring of the plate-
let count may be all that is required, with rapid recovery of
platelet count within days to weeks as drug is cleared. For
those with platelets of less than 10 × 109/L, and/or with bleed-
ing, or risk factors for bleeding, such as sepsis, or other blood
abnormalities, platelet transfusion is considered [9]. Use of
corticosteroids, intravenous immunoglobulins, and plasma ex-
change, has also been described, but the benefit of these is
uncertain [6].
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Drug induces direct anti-platelet
antibodies that adhere to their target in
the absence of soluble drug in serum
Gold salts, penicillamine
Drug dependent antibody induction
Drug induces antibodies that bind to
platelet membrane proteins only in the
presence of soluble drug in the serum.
Presence of circulating drug-
dependent antibodies is highly





Drug links covalently to platelet




Drugs bind to Platelet Factor 4,
producing a complex on the surface of
platelets, to which the patient
generates antibodies, resulting in both
platelet activation and destruction
Heparin
Fiban-induced thrombocytopenia
Drug reacts with platelet membrane
glycoprotein IIb/IIIa and induces a




Naturally occurring or induced antibody
is specific for a murine component of
abiciximab, a chimeric antibody
therapy to GPIIIa, present on platelets
Abciximab
Table 2 Proposed criterion for the diagnosis of DITP. Definite
diagnosis: criteria 1, 2, 3 and 4 are met, diagnosis probable: criteria 1, 2
and 3 are met; diagnosis possible: criteria 1 met; diagnosis unlikely:
criterion 1 not met [8]
Criterion Description
1 Therapy with suspected drug preceded thrombocytopenia and
recovery from thrombocytopenia was complete and
sustained after discontinuation of the suspected drug
2 The suspected drug was the only drug used before the onset of
thrombocytopenia or other drugs were continued or re-
introduced after discontinuation with the suspected drug,
with a sustained normal platelet count
3 Other causes of thrombocytopenia have been excluded
4 Response to the suspected drug resulted in recurrence of the
thrombocytopenia
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